Valuation: GENinCode Plc

Market Cap 6.66M 9.03M 7.8M 7.32M 12.53M 864M 12.7M 85.77M 33.61M 433M 33.92M 33.18M 1.44B P/E 2026 *
-1.26x
P/E 2027 * -
Enterprise Value 5.86M 7.95M 6.86M 6.44M 11.03M 760M 11.18M 75.48M 29.58M 381M 29.85M 29.2M 1.27B EV / Sales 2026 *
1.24x
EV / Sales 2027 * -
Free-Float
59.68%
Yield 2026 *
-
Yield 2027 * -
1 day+2.43%
1 week-4.58%
Current month+13.31%
1 month+13.31%
3 months-11.56%
6 months-13.67%
Current year-62.23%
1 week 0.85
Extreme 0.85
0.95
1 month 0.75
Extreme 0.75
1
Current year 0.75
Extreme 0.75
2.5
1 year 0.75
Extreme 0.75
5.5
3 years 0.75
Extreme 0.75
13
5 years 0.75
Extreme 0.75
47
10 years 0.75
Extreme 0.75
48
Manager TitleAgeSince
Chief Operating Officer 51 05/09/2018
Chief Executive Officer 62 05/09/2018
Director of Finance/CFO 57 31/10/2020
Director TitleAgeSince
Chairman 62 05/09/2018
Director/Board Member 51 05/09/2018
Director/Board Member 65 30/04/2020
Date Insider Type Main position Quantity % Market Cap.
06/05/26 Free

Director

1,267,852 0.1684%
06/05/26 Free

Director

2,535,704 0.3367%
26/03/25 Free

Director

172,188 0.0973%
Change 5-day change 1-year change 3-year change Capi.($)
+2.43%-4.58%-35.25%-92.89% 9.03M
-0.73%-2.56%+170.49%+334.64% 21.7B
-0.28%-1.83%-43.04%-21.68% 9.9B
-2.89%-2.96%+321.62%+24.23% 7.56B
-0.24%+0.05%+79.97%+51.98% 6.59B
-3.12%-9.55%-41.78% - 6.11B
+3.89%+9.04%-9.18%-3.26% 6B
-1.73%+2.81%+83.84%+112.31% 4.7B
-1.15%-3.89%-13.15%-18.04% 4.27B
+4.53%+4.60%-17.46%-30.47% 2.79B
Average +0.06%+1.02%+49.61%+39.65% 6.96B
Weighted average by Cap. -0.59%-0.61%+89.18%+124.67%

Financials

2026 *2027 *
Net sales 4.73M 6.41M 5.54M 5.2M 8.9M 613M 9.02M 60.9M 23.87M 307M 24.08M 23.56M 1.02B -
Net income -5.02M -6.8M -5.87M -5.51M -9.44M -651M -9.57M -64.6M -25.31M -326M -25.54M -24.99M -1.08B -
Net Debt -800K -1.08M -936K -878K -1.5M -104M -1.53M -10.3M -4.03M -51.95M -4.07M -3.98M -173M -
Logo GENinCode Plc
GENinCode Plc is a United Kingdom-based predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer. Its testing products include CARDIO inCode Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA Test. Its SITAB is an online Web portal, which provides health care practitioners with a systemized approach to request, record, process and report their clinical and genetic test results. Its CARDIO inCode Score is a genetic test for the evaluation of the coronary genetic load based on a polygenic risk score.
Employees
44
Date Price Change Volume
18/08/26 GBX 0.9065 +2.43% 901,561
17/08/26 GBX 0.8850 0.00% 1,005,537
14/08/26 GBX 0.8850 -1.67% 1,769,968
13/08/26 GBX 0.9000 0.00% 226,306
12/08/26 GBX 0.9000 -5.26% 743,998
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.008850GBP
Average target price
0.0750GBP
Spread / Average Target
+747.46%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENI Stock